查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999204

人類藥物敏感性檢測市場：按產品類型、技術、檢測類型、病原體、應用和最終用戶分類－2026-2032年全球市場預測

Human Antimicrobial Susceptibility Testing Market by Product, Technology, Test Type, Pathogen, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人類藥物敏感性測試市場價值將達到 41.6 億美元，到 2026 年將成長至 44.3 億美元，到 2032 年將達到 65 億美元，複合年成長率為 6.55%。

主要市場統計數據
基準年 2025 41.6億美元
預計年份：2026年 44.3億美元
預測年份 2032 65億美元
複合年成長率 (%) 6.55%

一篇極具影響力的引言，概述了臨床、操作和技術因素的融合，這些因素將重塑全球抗菌藥物敏感性測試實踐。

人類藥物敏感性檢測正處於轉折點，其驅動力來自臨床壓力、檢查室工作流程的演變以及技術的快速成熟。隨著多重細菌感染疾病的複雜性日益增加、抗藥性機制的不斷湧現以及對快速、有效結果的需求不斷成長，臨床團隊對藥物敏感性檢測結果的可靠性和速度都提出了更高的要求。同時，研究機構和製藥合作夥伴也越來越需要標準化、可重複的檢測平台，以便將其整合到藥物研發流程和轉化研究中。

定義變革性的技術和商業性變革，這些變革加速了整個藥敏試驗工作流程中的自動化、分子雜合反應和軟體整合。

抗菌藥物敏感性檢測領域正經歷一場變革，這場變革的驅動力來自自動化、分子技術的整合以及軟體驅動的決策支援。自動化系統正逐步減少人工操作所需的時間和操作誤差，使檢查室能夠在不相應增加人員配置的情況下擴大檢測能力。軟體平台進一步強化了這項變革，這些平台能夠整合檢測結果、進行趨勢分析並提供以合理用藥為重點的報告，從而使抗菌藥物敏感性檢測（AST）從一項獨立的檢查室操作轉變為臨床決策流程中不可或缺的一部分。

評估美國在 2025 年實施的關稅變更對檢驗材料採購和實驗室持續營運的累積影響和供應鏈影響。

2025年關稅措施和貿易政策調整的實施，對與抗菌藥物敏感性檢測相關的檢查室、製造商和分銷網路產生了複雜的下游影響。關鍵進口設備、試劑和組件的進口前置作業時間增加以及監管摩擦延長了採購週期，迫使採購團隊重新評估總到岸成本。因此，供應鏈規劃正從週期性採購轉向持續的風險規避和多源採購策略。

將產品、技術、測試類型、應用、最終用戶和病原體維度與實際採購和驗證要求連結起來的綜合細分洞察。

一套精細的細分框架揭示了臨床需求、技術能力和採購行為如何在產品、技術、檢測類型、應用、最終用戶和病原體等維度上相互交織。產品差異化涵蓋儀器、試劑和耗材以及軟體，其中儀器又細分為桌上型和無人值守式兩種類型，試劑和耗材則包括試劑盒、試劑盤、培養基和試紙條。每個類別都為檢查室帶來了獨特的驗證、庫存和成本的考量。這種細緻的產品級分析指南確定採購優先順序。桌上型平台優先考慮空間節省和柔軟性，而無人值守式系統則優先考慮處理能力和整合性。

關鍵區域洞察揭示了法律規範、基礎設施投資和製造業趨勢如何影響美洲、歐洲、中東和非洲以及亞太地區的採用。

區域趨勢正在重塑美洲、歐洲、中東和非洲（EMEA）以及亞太地區的採購偏好、監管參與和創新應用。在美洲，對快速診斷和集中式檢測網路整合的高度重視，推動了對高通量自動化平台和整合資訊學的需求，以支援舉措。該地區的檢查室越來越注重快速交付檢測結果和擴充性，以應對複雜的病例量，這影響了儀器和耗材的選擇。

分析供應商的策略，優先考慮互通性、基於耗材的服務模式和監管合規性，以加強臨床和商業性地位。

抗菌藥物敏感性檢測領域的主要企業正日益關注平台間的互通性、以耗材主導的服務模式以及支持臨床決策和合理使用抗菌藥物的數據分析。供應商正透過改進與實驗室資訊系統的整合、提供自動化解讀報告以及生命週期服務來提升提案價值，從而減輕最終用戶的檢驗負擔。這些策略舉措優先考慮與臨床網路建立長期夥伴關係，而非一次性的儀器銷售。

為供應商和檢查室提供切實可行的策略建議，以增強整個藥敏試驗操作的韌性、互通性和臨床影響。

產業領導者應採取平衡策略，在推進自動化和分子檢測整合的同時，保持手動和分散式檢測環境的柔軟性。優先投資模組化和可互通平台，將使檢查室能夠在無需巨額資本投入的情況下擴展檢測能力。同時，與本地試劑生產商和經銷商建立牢固的夥伴關係，將增強供應韌性，並降低對單一供應商的依賴。

採用透明的混合方法研究途徑，結合文獻整合、與關鍵相關人員的訪談以及交叉檢驗資料的三角測量，以確保分析的嚴謹性。

本調查方法結合了系統性的第二手資料收集、有針對性的一手研究和嚴謹的資料三角驗證，確保了研究結果的可靠性和可重複性。二手研究包括對同儕審查文獻、監管指導文件、技術白皮書和公共採購政策的結構化審查，從而建立了技術能力、檢驗標準和監管預期方面的客觀基準。這一基礎層指南了一手研究的設計和分析假設的建構。

為了指導藥敏試驗的永續引入和臨床整合，總結了技術、操作和監管要求。

總之，藥物敏感性檢測正從單純的實驗室工作發展成為一項綜合性的臨床工具，支持快速治療決策、合理用藥和轉化研究。技術進步，特別是自動化、分子混合工作流程和軟體驅動的報告功能，帶來了新的效率和臨床價值，但也增加了檢驗、採購和供應鏈管理的複雜性。相關人員必須仔細權衡這些利弊，同時兼顧速度、準確性和操作可行性。

最終，現實的實驗、嚴格的檢驗以及與最終用戶的持續合作對於易感性測試的創新至關重要，才能帶來更好的患者治療效果和加強公共衛生準備。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人類藥物敏感度檢測市場：依產品分類

  • 裝置
    • 桌面型
    • 走開
  • 試劑和耗材
    • 磁碟
    • 成套工具
    • 媒體
    • 條
  • 軟體

第9章：人類藥物敏感性檢測市場：依技術分類

  • 自動化系統
    • 微型掃描系統
    • 鳳凰系統
    • 維泰克系統
  • 紙錠擴散法
  • 漸變條
  • 微量稀釋法
  • 分子方法

第10章：依檢測方法分類的人體藥物敏感性檢測市場

  • 自動化測試
  • 手動測試
    • 瓊脂稀釋法
    • 肉湯微量稀釋法
    • 紙錠擴散法
    • 漸變條

第11章 人類藥物敏感性檢測市場（依病原體分類）

  • 真菌
  • 革蘭氏陰性菌
    • 腸桿菌科
    • 非腸桿菌科
  • 革蘭氏陽性菌
  • 分枝桿菌

第12章：人類藥物敏感性檢測市場：依應用領域分類

  • 臨床診斷
  • 製藥
  • 研究

第13章：人類藥物敏感性檢測市場：依最終用戶分類

  • 診所
  • 測試機構
  • 醫院
  • 研究機構

第14章：人類藥物敏感性檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：人類藥物敏感性檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：人類藥物敏感性檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國人類藥物敏感性測試市場

第18章：中國人體藥物敏感性檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accelerate Diagnostics Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • HiMedia Laboratories Pvt. Ltd.
  • Liofilchem Srl
  • Luminex Corporation
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market was valued at USD 4.16 billion in 2025 and is projected to grow to USD 4.43 billion in 2026, with a CAGR of 6.55%, reaching USD 6.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.16 billion
Estimated Year [2026] USD 4.43 billion
Forecast Year [2032] USD 6.50 billion
CAGR (%) 6.55%

High-impact introduction outlining the converging clinical, operational, and technological forces reshaping antimicrobial susceptibility testing practices globally

The landscape of human antimicrobial susceptibility testing is at an inflection point driven by converging clinical pressures, evolving laboratory workflows, and accelerating technology maturation. Clinical teams confront increasing diagnostic complexity as polymicrobial infections, resistance mechanisms, and the need for rapid actionable results demand both robustness and speed in susceptibility outputs. At the same time, research and pharmaceutical partners are intensifying their demand for standardized, reproducible testing platforms that can integrate with drug development pipelines and translational studies.

Laboratories face competing priorities: maintaining regulatory compliance, reducing turnaround times, and optimizing reagent and instrument utilization while managing constrained budgets and skilled workforce shortages. These operational realities are reshaping procurement criteria, shifting the emphasis toward systems that deliver automation, connectivity, and validated performance across diverse specimen types. The introduction of advanced molecular and phenotypic hybrid workflows is redefining the role of AST as a bridge between identification and therapeutic stewardship.

Given these pressures, stakeholders must reconcile near-term clinical imperatives with long-term strategic investments. Cross-functional collaboration among clinicians, microbiologists, informaticians, and procurement teams is essential to translate diagnostic intelligence into improved patient outcomes. This introduction establishes the critical context and the main vectors of change that inform the deeper analysis in subsequent sections

Defining transformative technological and commercial shifts that are accelerating automation, molecular hybridization, and software integration across susceptibility testing workflows

The field of antimicrobial susceptibility testing is undergoing transformative shifts driven by automation, molecular integration, and software-enabled decision support. Automated systems are progressively reducing manual hands-on time and variability, enabling laboratories to scale capacity without proportionally expanding headcount. This transformation is reinforced by software platforms that consolidate results, enable trend analysis, and provide stewardship-focused reporting-shifting AST from a standalone laboratory procedure to an integral part of clinical decision pathways.

Parallel advances in molecular methods are enabling targeted detection of resistance determinants that complement phenotypic susceptibility outputs. Hybrid workflows that combine rapid molecular screening with confirmatory phenotypic testing are emerging as pragmatic solutions that balance speed and clinical relevance. Additionally, reagent and consumable innovations-such as pre-formulated media, stabilized strips, and kit-based reagents-are simplifying routine workflows and improving reproducibility across decentralized testing environments.

These shifts are also catalyzing changes in commercial strategy: vendors are prioritizing interoperable platforms, open data standards, and service models that extend beyond capital sales into consumable-based and data-driven revenue streams. As a result, clinical laboratories and research organizations must adapt procurement, validation, and IT integration approaches to fully realize the potential of these transformative technologies

Assessing the cumulative operational and supply chain consequences of United States tariff changes implemented in 2025 on testing procurement and laboratory continuity

The introduction of tariff measures and trade policy adjustments in 2025 has created complex downstream effects for laboratories, manufacturers, and distribution networks involved in antimicrobial susceptibility testing. Increased import duties and regulatory friction on key imported instruments, reagents, and components have amplified procurement lead times and prompted procurement teams to reassess total landed costs. As a consequence, supply chain planning has moved from periodic purchasing toward continuous risk mitigation and multi-sourcing strategies.

Manufacturers have responded by reassessing their global manufacturing footprints, increasing local production in tariff-affected jurisdictions, and reconfiguring supply networks to mitigate cost volatility. These shifts have altered decisions about inventory buffering, strategic stockpiling of critical consumables, and contractual terms with distributors. For laboratories, the practical implications include extended validation timelines for newly sourced products, potential substitutions that require cross-validation, and closer scrutiny of vendor service models to ensure continuity in testing capabilities during transition periods.

Looking ahead, sustained tariff-driven disruption can incentivize regional supply resilience and spur investments in domestic reagent and instrument production. At the same time, stakeholders must monitor regulatory harmonization efforts and trade negotiations that could ease friction. In this environment, flexible procurement strategies, enhanced supplier collaboration, and forward-looking validation protocols will be essential to preserve testing continuity and clinical reliability

Integrated segmentation insights linking product, technology, test type, application, end-user, and pathogen dimensions to practical procurement and validation imperatives

A nuanced segmentation framework reveals where clinical need, technological capability, and procurement behavior intersect across product, technology, test type, application, end user, and pathogen dimensions. Product differentiation encompasses instruments, reagents and consumables, and software, with instruments subdivided by bench top and walk-away modalities and reagents and consumables including discs, kits, media, and strips-each category driving distinct validation, inventory, and cost considerations for laboratories. This product-level granularity informs procurement priorities: bench top platforms often emphasize local footprint and flexibility, whereas walk-away systems prioritize throughput and integration.

Technology segmentation spans automated systems, disk diffusion, gradient strip, microdilution, and molecular methods; within automation, platform-level differentiation between MicroScan-style, Phoenix-style, and fully integrated Vitek-style systems determines interoperability and laboratory workflow redesign. Test type distinctions between automated testing and manual testing-where manual approaches include agar dilution, broth microdilution, disk diffusion, and gradient strip-highlight trade-offs between analytical precision and operational scalability. Applications range from clinical diagnostics to pharmaceutical development and research, with each use case imposing unique demands on validation rigor, traceability, and data integration.

End users such as clinics, diagnostic laboratories, hospitals, and research institutes each face different throughput profiles, capital constraints, and regulatory expectations, which influence adoption curves across the product and technology spectrum. Pathogen classification across fungi, gram negative bacteria, gram positive bacteria, and mycobacteria-along with finer distinctions such as Enterobacteriaceae versus non-Enterobacteriaceae within gram negatives-shapes reagent formulation needs, interpretive criteria, and susceptibility endpoint determination. Understanding these interdependent segmentation layers enables stakeholders to prioritize investments and tailor operational roadmaps

Critical regional insights revealing how regulatory frameworks, infrastructure investment, and manufacturing dynamics are shaping adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics are reshaping procurement preferences, regulatory interaction, and innovation diffusion across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a strong emphasis on rapid diagnostics and consolidation of centralized testing networks is driving demand for high-throughput automated platforms and integrated informatics that support stewardship initiatives. Laboratories in this region are increasingly focused on rapid turnaround and scalability to manage complex caseloads, which influences choices in instruments and consumables.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization efforts, public health priorities, and fiscal constraints create diverse adoption patterns. In parts of this geography, stringent regulatory pathways and centralized procurement models favor validated, standardized solutions; in other areas, decentralized laboratories prioritize cost-effective manual methods and localized reagent solutions. Asia-Pacific demonstrates rapid adoption of automation and molecular hybrid approaches, supported by expanding domestic manufacturing capabilities and strong investment in laboratory infrastructure. This region's scale and manufacturing density also make it a focal point for supply chain reconfiguration and reagent localization efforts.

Across all regions, local regulatory frameworks, reimbursement models, and workforce availability will continue to moderate adoption rates and shape vendor strategies. A clear understanding of regional priorities is essential for tailoring market entry, service models, and distribution partnerships that align with local laboratory operations and clinical governance

Analyzing vendor strategies that prioritize interoperability, consumable-based service models, and regulatory compliance to strengthen clinical and commercial positioning

Leading companies in the antimicrobial susceptibility testing ecosystem are increasingly oriented toward platform interoperability, consumable-driven service models, and data analytics that support clinical decision-making and antimicrobial stewardship objectives. Vendors are enhancing their value propositions by integrating laboratory information systems connectivity, automating interpretive reporting, and offering lifecycle services that reduce the validation burden on end users. These strategic moves prioritize long-term partnerships with clinical networks over single-transaction equipment sales.

Competitive differentiation is also emerging through reagent innovation, such as stabilized kits and simplified media formulations that reduce variability and improve shelf stability across diverse laboratory environments. Manufacturers are investing in modular systems that enable incremental upgrades, protecting capital investments while offering pathways to higher throughput and expanded test menus. Strategic alliances between instrument providers and molecular assay developers are accelerating hybrid workflows that can quickly translate resistance determinant detection into actionable susceptibility guidance.

Finally, companies are intensifying focus on regulatory compliance and localized support, recognizing that rapid service response and robust post-market surveillance are critical for clinical trust. This combination of product innovation, service orientation, and regulatory rigor defines the competitive contours of the market and informs procurement and partnership choices by hospitals, reference laboratories, and research organizations

Actionable strategic recommendations for vendors and laboratories to enhance resilience, interoperability, and clinical impact across susceptibility testing operations

Industry leaders should pursue a balanced strategy that advances automation and molecular integration while preserving flexibility for manual and decentralized testing contexts. Prioritizing investments in modular, interoperable platforms will allow laboratories to scale capabilities without committing to prohibitive capital outlays. Concurrently, establishing robust partnerships with regional reagent manufacturers and distributors will enhance supply resilience and reduce dependency on single-source supply chains.

Operationally, embedding data analytics and stewardship-oriented reporting into platform design will increase clinical impact and support hospital governance objectives. Vendors and laboratories alike should collaborate to standardize data formats and adopt APIs that facilitate integration with electronic health records and infection control systems. From a regulatory and quality perspective, accelerating validation pipelines through pre-approved protocols and harmonized method comparison studies will reduce time to deployment and ensure consistent performance across diverse settings.

Finally, stakeholders should adopt dynamic procurement approaches that incorporate total cost of ownership, service responsiveness, and validation burden into purchasing decisions. By aligning commercial models with clinical workflows and long-term support commitments, industry leaders can unlock sustainable adoption and improved patient outcomes while mitigating operational and supply chain disruptions

Transparent mixed-methods research approach combining literature synthesis, primary stakeholder interviews, and cross-validated data triangulation to ensure analytical rigor

The research methodology combines systematic secondary evidence gathering, targeted primary engagement, and rigorous data triangulation to ensure robust and reproducible insights. Secondary work included a structured review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public procurement policies to establish a factual baseline for technology capabilities, testing standards, and regulatory expectations. This foundational layer informed the design of primary interactions and the framing of analytical hypotheses.

Primary research incorporated structured interviews with laboratory directors, clinical microbiologists, procurement officers, and industry executives to capture operational realities, procurement drivers, and vendor performance perceptions. These engagements were designed to probe validation practices, reagent handling, workflow constraints, and post-market service expectations. Responses were coded and synthesized to identify recurring themes, regional differentiators, and operational pain points that inform practical recommendations.

Quantitative and qualitative inputs were triangulated through cross-validation across data sources, ensuring consistency and identifying outliers. Methodological quality controls included reproducibility checks, analyst peer review, and an audit trail documenting source provenance. This mixed-methods approach supports defensible conclusions and actionable guidance tailored to clinical, research, and commercial stakeholders

Concise conclusion synthesizing technological, operational, and regulatory imperatives to guide sustainable adoption and clinical integration of susceptibility testing

In conclusion, antimicrobial susceptibility testing is evolving from a discrete laboratory task into an integrated clinical asset that supports rapid therapeutic decision-making, stewardship initiatives, and translational research. Technological advances-particularly in automation, molecular hybrid workflows, and software-enabled reporting-are unlocking new efficiencies and clinical value, while also introducing complexity in validation, procurement, and supply chain management. Stakeholders must navigate these trade-offs deliberately, balancing speed, accuracy, and operational feasibility.

Regulatory dynamics, regional manufacturing trends, and trade policy shifts add layers of strategic consideration that influence procurement, service models, and vendor selection. Successful organizations will be those that invest in interoperable platforms, maintain diversified supply relationships, and embed data analytics into clinical workflows to demonstrate measurable impact. Collaboration across clinical, laboratory, and commercial functions will be essential to translate technological potential into reliable, everyday practice.

Ultimately, the path forward requires pragmatic experimentation, rigorous validation, and sustained engagement with end users to ensure that innovations in susceptibility testing deliver improved patient outcomes and enhanced public health preparedness

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Antimicrobial Susceptibility Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Bench Top
    • 8.1.2. Walk Away
  • 8.2. Reagents Consumables
    • 8.2.1. Discs
    • 8.2.2. Kits
    • 8.2.3. Media
    • 8.2.4. Strips
  • 8.3. Software

9. Human Antimicrobial Susceptibility Testing Market, by Technology

  • 9.1. Automated Systems
    • 9.1.1. MicroScan Systems
    • 9.1.2. Phoenix Systems
    • 9.1.3. Vitek Systems
  • 9.2. Disk Diffusion
  • 9.3. Gradient Strip
  • 9.4. Microdilution
  • 9.5. Molecular Methods

10. Human Antimicrobial Susceptibility Testing Market, by Test Type

  • 10.1. Automated Testing
  • 10.2. Manual Testing
    • 10.2.1. Agar Dilution
    • 10.2.2. Broth Microdilution
    • 10.2.3. Disk Diffusion
    • 10.2.4. Gradient Strip

11. Human Antimicrobial Susceptibility Testing Market, by Pathogen

  • 11.1. Fungi
  • 11.2. Gram Negative Bacteria
    • 11.2.1. Enterobacteriaceae
    • 11.2.2. Non Enterobacteriaceae
  • 11.3. Gram Positive Bacteria
  • 11.4. Mycobacteria

12. Human Antimicrobial Susceptibility Testing Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Pharmaceutical
  • 12.3. Research

13. Human Antimicrobial Susceptibility Testing Market, by End User

  • 13.1. Clinics
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Human Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Antimicrobial Susceptibility Testing Market

18. China Human Antimicrobial Susceptibility Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accelerate Diagnostics Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. bioMerieux SA
  • 19.8. Bruker Corporation
  • 19.9. Danaher Corporation
  • 19.10. F. Hoffmann-La Roche AG
  • 19.11. HiMedia Laboratories Pvt. Ltd.
  • 19.12. Liofilchem S.r.l.
  • 19.13. Luminex Corporation
  • 19.14. QIAGEN N.V.
  • 19.15. Siemens Healthineers AG
  • 19.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)